Merck Inc. announced that the European Commission has approved Keytruda (pembrolizumab) for the adjuvant treatment of adults with stage III...
Bristol-Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended...
Merck Inc., announced that the FDA has approved Keytruda, Merck�s anti-PD-1 therapy, for the adjuvant treatment of patients with melanoma...
Navidea Biopharmaceuticals, Inc. announced top-line results from the interim analysis of its Phase III clinical trial, NEO3-06, of Lymphoseek (technetium...
Bristol-Myers Squibb Company announced results of an interim descriptive analysis from an ongoing National Cancer Institute (NCI) Phase III randomized...
Bristol-Myers Squibb Company announced results of a three-year analysis of efficacy data from the Phase III CheckMate -238 study evaluating...
Bristol-Myers Squibb Company announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients...
This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in...
Merck announced new and updated findings from the Phase III EORTC1325/KEYNOTE-054 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma.
People with radioiodine-refractory differentiated thyroid cancer treated with Lenvima (lenvatinib), from Eisai, had greater tumour shrinkage than with placebo in...